Switch theme
Sign up to access all valuation multiples
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
1994
10.0K+
LTM Revenue $5.1B
LTM EBITDA $1.8B
$35.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ResMed has a last 12-month revenue (LTM) of $5.1B and a last 12-month EBITDA of $1.8B.
In the most recent fiscal year, ResMed achieved revenue of $4.7B and an EBITDA of $1.5B.
ResMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ResMed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.1B | XXX | $4.7B | XXX | XXX | XXX |
| Gross Profit | $3.0B | XXX | $2.7B | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $1.8B | XXX | $1.5B | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $1.7B | XXX | $1.4B | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $1.3B | XXX | $1.0B | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $469M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ResMed's stock price is $245.
ResMed has current market cap of $35.9B, and EV of $35.8B.
See ResMed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.8B | $35.9B | XXX | XXX | XXX | XXX | $9.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ResMed has market cap of $35.9B and EV of $35.8B.
ResMed's trades at 7.3x EV/Revenue multiple, and 21.1x EV/EBITDA.
Equity research analysts estimate ResMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ResMed has a P/E ratio of 26.6x.
See valuation multiples for ResMed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35.9B | XXX | $35.9B | XXX | XXX | XXX |
| EV (current) | $35.8B | XXX | $35.8B | XXX | XXX | XXX |
| EV/Revenue | 7.0x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | 19.4x | XXX | 21.1x | XXX | XXX | XXX |
| EV/EBIT | 21.1x | XXX | 23.1x | XXX | XXX | XXX |
| EV/Gross Profit | 11.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.6x | XXX | 29.9x | XXX | XXX | XXX |
| EV/FCF | 24.9x | XXX | 26.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialResMed's last 12 month revenue growth is 8%
ResMed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
ResMed's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ResMed's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ResMed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ResMed acquired XXX companies to date.
Last acquisition by ResMed was XXXXXXXX, XXXXX XXXXX XXXXXX . ResMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ResMed founded? | ResMed was founded in 1994. |
| Where is ResMed headquartered? | ResMed is headquartered in United States of America. |
| How many employees does ResMed have? | As of today, ResMed has 10.0K+ employees. |
| Who is the CEO of ResMed? | ResMed's CEO is Mr. Michael J. Farrell. |
| Is ResMed publicy listed? | Yes, ResMed is a public company listed on NYS. |
| What is the stock symbol of ResMed? | ResMed trades under RMD ticker. |
| When did ResMed go public? | ResMed went public in 1995. |
| Who are competitors of ResMed? | Similar companies to ResMed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ResMed? | ResMed's current market cap is $35.9B |
| What is the current revenue of ResMed? | ResMed's last 12 months revenue is $5.1B. |
| What is the current revenue growth of ResMed? | ResMed revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of ResMed? | Current revenue multiple of ResMed is 7.0x. |
| Is ResMed profitable? | Yes, ResMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ResMed? | ResMed's last 12 months EBITDA is $1.8B. |
| What is ResMed's EBITDA margin? | ResMed's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of ResMed? | Current EBITDA multiple of ResMed is 19.4x. |
| What is the current FCF of ResMed? | ResMed's last 12 months FCF is $1.4B. |
| What is ResMed's FCF margin? | ResMed's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of ResMed? | Current FCF multiple of ResMed is 24.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
